- Home
- SITC vs EOLS Comparison
SITC vs EOLS Comparison
Compare SITC & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- EOLS
- Stock Information
- Founded
- SITC 1965
- EOLS 2012
- Country
- SITC United States
- EOLS United States
- Employees
- SITC N/A
- EOLS N/A
- Industry
- SITC Real Estate Investment Trusts
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- EOLS Health Care
- Exchange
- SITC Nasdaq
- EOLS Nasdaq
- Market Cap
- SITC 786.5M
- EOLS 702.2M
- IPO Year
- SITC 1993
- EOLS 2018
- Fundamental
- Price
- SITC $14.61
- EOLS $13.99
- Analyst Decision
- SITC Hold
- EOLS Strong Buy
- Analyst Count
- SITC 9
- EOLS 6
- Target Price
- SITC $38.78
- EOLS $23.80
- AVG Volume (30 Days)
- SITC 683.6K
- EOLS 802.6K
- Earning Date
- SITC 02-27-2025
- EOLS 03-04-2025
- Dividend Yield
- SITC 7.15%
- EOLS N/A
- EPS Growth
- SITC 757.51
- EOLS N/A
- EPS
- SITC 13.71
- EOLS N/A
- Revenue
- SITC $451,683,000.00
- EOLS $248,326,000.00
- Revenue This Year
- SITC N/A
- EOLS $34.38
- Revenue Next Year
- SITC N/A
- EOLS $31.94
- P/E Ratio
- SITC $1.06
- EOLS N/A
- Revenue Growth
- SITC N/A
- EOLS 34.42
- 52 Week Low
- SITC $14.47
- EOLS $9.25
- 52 Week High
- SITC $64.44
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- SITC 40.76
- EOLS 54.04
- Support Level
- SITC $14.53
- EOLS $14.50
- Resistance Level
- SITC $14.84
- EOLS $15.06
- Average True Range (ATR)
- SITC 0.35
- EOLS 0.86
- MACD
- SITC -0.02
- EOLS -0.00
- Stochastic Oscillator
- SITC 17.18
- EOLS 27.38
About SITC SITE Centers Corp.
SITE Centers Corp is a United States-based self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.